Technical Analysis for NSPX - Inspyr Therapeutics Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
See historical NSPX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Spinning Top | Other | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | -12.50% | |
NR7 | Range Contraction | -12.50% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Biotechnology
Inspyr Therapeutics, Inc., formerly GenSpera, Inc., is an early-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, renal and other cancers. Its technology platform combines a plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that targets the release of the drug within the solid tumor. Its cancer prodrugs provide a targeted therapeutic approach to a range of solid tumors. Its product candidates include Mipsagargin, G-115, G-114 and G-301. Its lead drug candidate, mipsagargin, is activated by the enzyme prostate specific membrane antigen (PSMA), which is found in prostate epithelial cells in the normal prostate, in prostate cancer cells, and in vascular endothelial cells (blood vessels) found in solid tumors. Mipsagargin is in Phase II clinical evaluation in glioblastoma patients.
Chemistry RTT Cancer Pharmaceutical Biology Solid Tumors Prostate Cancer Glioblastoma Cancer Therapeutics Solid Tumor Northwest Biotherapeutics Genspera Glutamate Carboxypeptidase Ii Prodrug Cancer
Chemistry RTT Cancer Pharmaceutical Biology Solid Tumors Prostate Cancer Glioblastoma Cancer Therapeutics Solid Tumor Northwest Biotherapeutics Genspera Glutamate Carboxypeptidase Ii Prodrug Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Date | Title |
---|
Indicator | Value |
---|---|
52 Week High | 0.0316 |
52 Week Low | 0.0015 |
Average Volume | 470,379 |
200-Day Moving Average | 0.0062 |
50-Day Moving Average | 0.0100 |
20-Day Moving Average | 0.0096 |
10-Day Moving Average | 0.0089 |
Average True Range | 0.0025 |
ADX | 12.19 |
+DI | 21.5339 |
-DI | 21.5339 |
Chandelier Exit (Long, 3 ATRs ) | 0.0105 |
Chandelier Exit (Short, 3 ATRs ) | 0.0145 |
Upper Bollinger Band | 0.0121 |
Lower Bollinger Band | 0.0071 |
Percent B (%b) | -0.02 |
BandWidth | 52.0833 |
MACD Line | -0.0008 |
MACD Signal Line | -0.0004 |
MACD Histogram | -0.0004 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.0085 | ||||
Resistance 3 (R3) | 0.0087 | 0.0083 | 0.0083 | ||
Resistance 2 (R2) | 0.0083 | 0.0080 | 0.0083 | 0.0082 | |
Resistance 1 (R1) | 0.0077 | 0.0077 | 0.0075 | 0.0075 | 0.0081 |
Pivot Point | 0.0073 | 0.0073 | 0.0073 | 0.0073 | 0.0073 |
Support 1 (S1) | 0.0067 | 0.0070 | 0.0065 | 0.0065 | 0.0059 |
Support 2 (S2) | 0.0063 | 0.0067 | 0.0063 | 0.0058 | |
Support 3 (S3) | 0.0057 | 0.0063 | 0.0058 | ||
Support 4 (S4) | 0.0055 |